Condensed Consolidated Statements of Changes in Equity (unaudited) - USD ($) $ in Millions	Total	Total Baxter stockholders' equity	Common stock	Common stock in treasury	Additional contributed capital	Retained earnings	Accumulated other comprehensive income (loss)	Noncontrolling interests
Balance, beginning of period (in shares) at Dec. 31, 2023			683,000,000
Balance, beginning of period (in usd) at Dec. 31, 2023	$ 8,468	$ 8,402	$ 683	$ (11,230)	$ 6,389	$ 16,114	$ (3,554)	$ 66
Balance, treasury, beginning period (in shares) at Dec. 31, 2023				176,000,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(272)	(277)				(277)		5
Other comprehensive income (loss)	(278)	(274)					(274)	(4)
Stock issued under employee benefit plans and other (in shares)				(3,000,000)
Stock issued under employee benefit plans and other	90	90		$ 126	(36)
Dividends declared on common stock	(298)	(298)				(298)
Change in noncontrolling interests	(2)							(2)
Balance, end of period (in shares) at Jun. 30, 2024			683,000,000
Balance, end of period (in usd) at Jun. 30, 2024	7,708	7,643	$ 683	$ (11,104)	6,353	15,539	(3,828)	65
Balance, treasury, ending period (in shares) at Jun. 30, 2024				173,000,000
Balance, beginning of period (in shares) at Mar. 31, 2024			683,000,000
Balance, beginning of period (in usd) at Mar. 31, 2024	8,235	8,173	$ 683	$ (11,130)	6,339	16,003	(3,722)	62
Balance, treasury, beginning period (in shares) at Mar. 31, 2024				174,000,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(311)	(314)				(314)		3
Other comprehensive income (loss)	(106)	(106)					(106)	0
Stock issued under employee benefit plans and other (in shares)				(1,000,000)
Stock issued under employee benefit plans and other	40	40		$ 26	14
Dividends declared on common stock	(150)	(150)				(150)
Balance, end of period (in shares) at Jun. 30, 2024			683,000,000
Balance, end of period (in usd) at Jun. 30, 2024	7,708	7,643	$ 683	$ (11,104)	6,353	15,539	(3,828)	65
Balance, treasury, ending period (in shares) at Jun. 30, 2024				173,000,000
Balance, beginning of period (in shares) at Dec. 31, 2024			683,000,000
Balance, beginning of period (in usd) at Dec. 31, 2024	$ 7,024	6,964	$ 683	$ (11,059)	6,421	14,929	(4,010)	60
Balance, treasury, beginning period (in shares) at Dec. 31, 2024	172,567,636			173,000,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	$ 217	217				217		0
Other comprehensive income (loss)	149	149					149	0
Reclassification of other comprehensive income (loss) disposed in the Kidney Care separation	115	115					115
Stock issued under employee benefit plans and other (in shares)				(3,000,000)
Stock issued under employee benefit plans and other	51	51		$ 144	(93)
Dividends declared on common stock	(176)	(176)				(176)
Disposition of noncontrolling interest associated with the Kidney Care separation	(87)							(87)
Balance, end of period (in shares) at Jun. 30, 2025			683,000,000
Balance, end of period (in usd) at Jun. 30, 2025	$ 7,293	7,320	$ 683	$ (10,915)	6,328	14,970	(3,746)	(27)
Balance, treasury, ending period (in shares) at Jun. 30, 2025	169,996,752			170,000,000
Balance, beginning of period (in shares) at Mar. 31, 2025			683,000,000
Balance, beginning of period (in usd) at Mar. 31, 2025	$ 7,054	7,081	$ 683	$ (10,937)	6,309	14,968	(3,942)	(27)
Balance, treasury, beginning period (in shares) at Mar. 31, 2025				170,000,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	91	91				91		0
Other comprehensive income (loss)	196	196					196
Stock issued under employee benefit plans and other	41	41		$ 22	19
Dividends declared on common stock	(89)	(89)				(89)
Balance, end of period (in shares) at Jun. 30, 2025			683,000,000
Balance, end of period (in usd) at Jun. 30, 2025	$ 7,293	$ 7,320	$ 683	$ (10,915)	$ 6,328	$ 14,970	$ (3,746)	$ (27)
Balance, treasury, ending period (in shares) at Jun. 30, 2025	169,996,752			170,000,000